it activates both GLP-1 and another hormone known as GIP (glucose-dependent insulinotropic polypeptide)
Oral GLP-1 medicines are available for weight management, including orforglipron (Foundayo), approved by the FDA in April 2026, and an oral form of semaglutide
Key takeaway: How cannabis affects antidepressant treatment can differ significantly based on dosage, frequency of use, and the class of antidepressant medication
And that's all independent of estrogen pathways that, you know, when you look at that together, they may address metabolic dysfunction from complimentary angles and help improve insulin's action, reduce caloric load shift fat distribution, help with that metabolic profile of visceral fat
The same mental health issues we see with bariatric surgery, were going to see in psychological weight agents
Ozempic may affect the absorption of oral medications